GeneVax
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $160M
Overview
Creating next-generation gene-based vaccines for infectious diseases and cancer immunotherapies.
VaccinesOncology
Technology Platform
Platform focuses on advanced antigen design and gene delivery systems to create vaccines that elicit robust and durable immune responses.
Funding History
1Total raised:$160M
PIPE$160M
Opportunities
Potential to address unmet needs in vaccine development for challenging pathogens or to improve cancer vaccine efficacy.
Risk Factors
High technical and clinical development risk in a field with formidable, well-resourced competitors.
Competitive Landscape
Faces intense competition from established mRNA giants and numerous biotechs in the gene-based vaccine and cancer neoantigen space.